Chengdu, China, April 19, 2022
Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader
Chengdu, China, April 19, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that its Founder, President and CEO, Dun Yang, PhD has been named as a 2022 In Vivo Rising Leader.
In Vivo’s 30 Rising Leaders launched in 2020 and is updated annually. The 30 people spotlighted on the list are selected by In Vivo’s editorial team. The focus is on entrepreneurs and innovators who represent the next wave of creativity in health care. The list includes academics, CEOs of small and mid-sized companies, rising employees in larger biopharma and MedTech businesses, as well as people doing exciting work to drive better health initiatives worldwide.
With more than 25 years of research experience in biochemistry, cell and cancer biology gained in China and the USA, and a track record of top tier academic publications, Dr. Yang has set his sights on translating scientific breakthroughs into novel therapies to help cancer patients worldwide.
Commenting on his selection in the list ACB’s CEO, Dun Yang, PhD said: “It is an honor to have been selected as one of In Vivo’s 30 Rising Leaders for 2022. Congratulations also to the other awardees. My selection in this year’s list reflects the quality of the fast-emerging biotech sector in China and I am very excited for our future as we pursue our goal of translating scientific breakthroughs into novel therapies to help cancer patients worldwide. The day our first drug gets marketing approval will be the day my personal ambitions are realized.”
After completing his Ph.D. in biochemistry at Columbia University, Dr. Yang worked and was mentored in one of the most prolific cancer research laboratories in the US, that of Nobel laureate Dr. J. Michael Bishop at the University of California, San Francisco. The two academic successes he can be credited with that standout are the invention of the esiRNA method of gene silencing and pioneering research around MYC synthetic lethal drug interactions.
In 2016, Dr. Yang moved to China as a founding director of the J. Michael Bishop Institute of Cancer Research (MBICR). MBICR has now grown to where it is headquartered in the Tianfu International BioTown, Chengdu, China, employs a large team of basic and translational cancer researchers, and is advised by an advisory board comprised of nine preeminent scientists in the world. He also founded the company, Anticancer Bioscience (ACB), to translate and commercialize discoveries made at the MBICR.
ACB is a growing precision therapeutics company headquartered in Chengdu, China, with global research and development teams in India, Australia, the United Kingdom, and the United States. It is applying synthetic lethal approaches to develop targeted cancer therapies that have the potential to be much safer and more effective than current therapies. ACB has access to world-leading cancer biology expertise and proprietary drug discovery platforms that enable the company to identify novel compounds that can target both genetic and epigenetic vulnerabilities of cancer cells. ACB has bespoke chemical compound libraries, and AI-driven small molecule libraries, and has invested in developing one of the world’s largest natural product libraries, providing a rich screening resource for potential cancer therapeutics.
For further information, please contact:
At the company
+44 (0) 7968 726585
About Anticancer Bioscience
Anticancer Bioscience (ACB) is an international private company, commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between the founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY131M (around USD21M) and has around 50 employees in Chengdu, China, Hyderabad, India, Sydney, Australia, St Andrews, UK, and San Francisco, USA.